Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIA | Q9BZP6 | 19/20 | 0.67 |
| ▸ | CHIT1 | Q13231 | 18/20 | 0.67 |
| ▸ | CHI3L1 | P36222 | 14/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.67 |
| ▸ | CHI3L2 | Q15782 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26210447 | 0.91 | CHIA (0.70) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| SCHEMBL25383918 | 0.90 | CHIA (0.62) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| SCHEMBL25383929 | 0.89 | CHIA (0.62) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| SCHEMBL26210424 | 0.89 | CHIA (0.71) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| Trifluoroacetic Acid SCHEMBL25383921 | 0.87 | CHIA (0.65) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| Trifluoroacetic Acid SCHEMBL25384839 | 0.85 | CHIA (0.67) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| SCHEMBL26210418 | 0.85 | CHIA (0.75) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| Trifluoroacetic Acid SCHEMBL25384022 | 0.83 | CHIA (0.66) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| SCHEMBL26221680 | 0.83 | CHIA (0.58) | CHIACHIT1CHI3L1KCNH2CHI3L2 | |
| SCHEMBL25384305 | 0.82 | CHIA (0.75) | CHIACHIT1CHI3L1KCNH2CHI3L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CHIA 3/4885CHIT1 4/4885CHI3L1 1/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | CHIA 3/4885CHIT1 5/4885CHI3L1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.